Disc Medicine, Inc.
IRON- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001816736
In the last 90 days, Disc Medicine, Inc. insiders filed 0 open-market purchases and 9 sales; 216 institutions reported holding it in 13F filings for Q2 2026, worth $3.13B in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Disc Medicine, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 112
- +22 vs. Q3 2023
- Shares held
- 20.2M
- +342.3K (+1.7%) vs. Q3 2023
- Total value
- $1.17B
- +$233.8M (+25.1%) vs. Q3 2023
- New holders
- 32
- 41 more added
- Sold out
- 10
- 28 more reduced
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IRON on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 216 | $3.13B |
| Q1 2026 | 203 | $2.67B |
| Q4 2025 | 197 | $3.04B |
| Q3 2025 | 168 | $2.26B |
| Q2 2025 | 152 | $1.80B |
| Q1 2025 | 157 | $1.65B |
| Q4 2024 | 152 | $1.68B |
| Q3 2024 | 132 | $1.35B |
| Q2 2024 | 121 | $1.24B |
| Q1 2024 | 130 | $1.38B |
| Q4 2023 | 112 | $1.17B |
| Q3 2023 | 91 | $934.0M |
| Q2 2023 | 90 | $848.7M |
| Q1 2023 | 45 | $309.6M |
| Q4 2022 | 35 | $215.8M |
| Q3 2022 | 44 | $43.9M |
| Q2 2022 | 51 | $43.8M |
| Q1 2022 | 57 | $39.6M |
| Q4 2021 | 62 | $93.8M |
| Q3 2021 | 62 | $103.5M |
| Q2 2021 | 55 | $165.3M |
| Q1 2021 | 49 | $346.6M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Disc Medicine, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Polar Capital Holdings Plc | 546,915 | $31.6M | 0.22% | 00.0% | Unchanged |
| State Street Corp | 559,195 | $32.3M | 0.00% | −108,106−16.2% | Reduced |
| Price T Rowe Associates Inc | 590,831 | $34.1M | 0.00% | +63,092+12.0% | Added |
| Adage Capital Partners GP, L.L.C. | 750,000 | $43.3M | 0.09% | −558,405−42.7% | Reduced |
| Vanguard Group Inc | 764,544 | $44.2M | 0.00% | +99,092+14.9% | Added |
| Frazier Life Sciences Management, L.P. | 785,000 | $45.3M | 2.42% | +130,000+19.8% | Added |
| BlackRock Inc. | 868,440 | $50.2M | 0.00% | +224,109+34.8% | Added |
| Perceptive Advisors LLC | 1,023,045 | $59.1M | 1.32% | +127,404+14.2% | Added |
| Bain Capital Life Sciences Investors, LLC | 1,332,545 | $77.0M | 7.38% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 1,702,237 | $98.3M | 1.97% | −567,400−25.0% | Reduced |
| Paradigm Biocapital Advisors LP | 2,385,857 | $137.8M | 6.46% | +1,113,578+87.5% | Added |
| Atlas Venture Life Science Advisors, LLC | 2,555,172 | $147.6M | 17.58% | −190,163−6.9% | Reduced |
| Novo Holdings A/S | 0 | $0 | 0.00% | −1,090,772−100.0% | Sold out |
| Sphera Funds Management Ltd. | 0 | $0 | 0.00% | −111,398−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −86,000−100.0% | Sold out |
| Trustees of Columbia University in the City of New York | 0 | $0 | 0.00% | −78,682−100.0% | Sold out |
| Assenagon Asset Management S.A. | 0 | $0 | 0.00% | −74,164−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −25,330−100.0% | Sold out |
| Trexquant Investment LP | 0 | $0 | 0.00% | −12,534−100.0% | Sold out |
| Allspring Global Investments Holdings, LLC | 0 | $0 | 0.00% | −232−100.0% | Sold out |
| Ulland Investment Advisors, LLC | 0 | $0 | 0.00% | −34−100.0% | Sold out |
| Nisa Investment Advisors, LLC | 0 | $0 | 0.00% | −9−100.0% | Sold out |
| CHI Advisors LLC | – | – | – | – | Not filed |